Welcome to our dedicated page for Forte Biosciences SEC filings (Ticker: FBRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Forte Biosciences, Inc. filings document a clinical-stage biopharmaceutical issuer focused on FB102, a proprietary anti-CD122 monoclonal antibody therapeutic candidate for autoimmune and autoimmune-related diseases. Its 8-K reports cover operating and financial results, Regulation FD clinical disclosures, material events, capital-structure matters and exhibits such as press releases and clinical presentations.
Proxy materials describe annual meeting matters, stockholder voting, board and compensation governance and equity incentive plan administration. The filing record also identifies Forte’s common stock, par value $0.001 per share, listed on Nasdaq under the symbol FBRX.
Avena Merger Sub Inc., a wholly owned subsidiary of argenx BV, has made a cash tender offer to acquire all outstanding shares of Forte Biosciences, Inc. common stock. The offer price is $77.00 per share, net to the seller in cash, without interest and subject to applicable withholding taxes.
The offer is being made on the terms and conditions set out in an Offer to Purchase dated August 6, 2026 and a related Letter of Transmittal
Forte Biosciences, Inc. entered into an Agreement and Plan of Merger with argenx BV and its wholly owned subsidiary Avena Merger Sub Inc. under which Merger Sub has commenced a cash tender offer to acquire all outstanding shares of Forte common stock at $77.00 per share, net to the seller in cash, without interest, subject to tax withholding.
The offer covers all issued and outstanding shares; Forte reported 21,229,087 shares outstanding as of August 5, 2026, plus additional shares issuable under options, RSUs, the ESPP and pre-funded warrants. The offer is scheduled to expire at one minute after 11:59 p.m. Eastern Time on August 26, 2026, unless extended or earlier terminated pursuant to the Merger Agreement.
Subject to satisfaction or waiver of offer conditions, Merger Sub will promptly accept and pay for tendered shares and then, under Section 251(h) of the DGCL, merge with and into Forte without a stockholder vote, with Forte surviving as a wholly owned subsidiary of argenx. Each share (other than specified excluded or appraisal shares) will be converted in the merger into the right to receive the same $77.00 cash consideration. Forte’s board unanimously determined the transaction is fair and in the best interests of stockholders and recommends that stockholders accept the offer and tender their shares.
argenx BV, through its wholly owned subsidiary Avena Merger Sub Inc., has commenced a cash tender offer to acquire all outstanding shares of common stock of Forte Biosciences, Inc. at $77.00 per share, net to the seller in cash, without interest and subject to applicable tax withholding.
The offer is being made on the terms and subject to the conditions set out in an Offer to Purchase dated August 6, 2026 and a related Letter of Transmittal, which are being sent to Forte stockholders together with Forte’s Schedule 14D-9 filed with the SEC. The transaction is supported by an Agreement and Plan of Merger dated July 26, 2026 among Forte, argenx BV and Avena Merger Sub Inc., and a separate Tender and Support Agreement with certain Forte stockholders, both incorporated by reference.
argenx, through its wholly owned subsidiary Avena Merger Sub Inc., plans to launch a tender offer for all outstanding shares of common stock of Forte Biosciences, Inc. pursuant to an Agreement and Plan of Merger dated July 26, 2026.
The tender offer has not yet commenced and this communication is preliminary only. A detailed offer to purchase on Schedule TO and Forte’s Schedule 14D-9 recommendation statement will be filed with the SEC. The text highlights numerous risks, including potential failure to complete the tender offer or merger, regulatory approval conditions, competing proposals, possible termination of the merger agreement (including a termination fee), business disruption, and potential stockholder litigation.
BlackRock, Inc. has reported a significant ownership position in Forte Biosciences Inc. common stock on a Schedule 13G. BlackRock and certain of its business units are deemed to beneficially own 1,204,632 shares of Forte Biosciences common stock, representing 5.9% of the class.
Within this position, BlackRock has sole voting power over 1,186,954 shares and sole dispositive power over all 1,204,632 shares, with no shared voting or dispositive power reported. The filing notes that various underlying clients or persons have the right to receive dividends or sale proceeds from these shares, but that no single such person has an interest exceeding five percent of Forte Biosciences’ outstanding common shares.
The reported holdings reflect only the aggregated position of specified BlackRock reporting business units and exclude other BlackRock units whose holdings are disaggregated under SEC Release No. 34-39538.
argenx, through its wholly owned subsidiary Avena Merger Sub Inc., plans to commence a cash tender offer for all outstanding shares of common stock of Forte Biosciences, Inc. pursuant to an Agreement and Plan of Merger dated July 26, 2026. The communication describes that the tender offer has not yet begun and that the actual offer will proceed only via a formal offer to purchase, letter of transmittal and related documents filed on Schedule TO, followed by Forte’s response on Schedule 14D-9. It emphasizes that investors will be able to access these documents for free on the SEC’s website and the companies’ investor relations sites and highlights extensive forward-looking statement language outlining risks that could affect completion and timing of the tender offer and merger.
Forte Biosciences, Inc. agreed to be acquired by argenx via a two‑step transaction, starting with a cash tender offer at $77.00 per share, implying approximately $2.2 billion in equity value. Forte’s board unanimously recommended that stockholders accept the offer and tender their shares.
The tender offer will start within 10 business days, remain open at least 15 business days, and is conditioned on shares tendered exceeding 50% of those outstanding, Hart‑Scott‑Rodino clearance and other customary conditions, but not on financing. Following a successful offer, a short‑form merger under DGCL Section 251(h) will close at the same cash price, cashing out in‑the‑money options and RSUs and cancelling out‑of‑the‑money options. The merger agreement includes a $65 million termination fee in specified scenarios and a no‑shop with a fiduciary “Superior Offer” exception. Directors and officers holding about 1% of shares signed tender and support agreements. Closing is expected in Q3 2026.
Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander report beneficial ownership of 655,199 shares of Forte Biosciences, Inc. common stock, representing 3.2% of the common stock class.
The reporting persons have no sole voting or dispositive power and instead report shared voting and shared dispositive power over all 655,199 shares. The securities are held by affiliated entities over which they exercise voting control or investment discretion, and they state this disclosure should not itself be construed as an admission of beneficial ownership. They also confirm ownership of 5 percent or less of the class.
Forte Biosciences reported positive Phase 1b results for FB102 in vitiligo from a double-blind, placebo-controlled study of 43 subjects. Patients were randomized 3:1, with 32 on FB102 and 11 on placebo.
The primary endpoint was facial vitiligo area severity index (FVASI) percent improvement at week 24. In the efficacy-evaluable population, FB102 achieved a 29.6% mean FVASI improvement from baseline versus 7.9% on placebo, for a placebo-adjusted benefit of 21.7 percentage points (p=0.020). Statistically significant separation from placebo emerged by day 64 and continued through week 24 after the 12‑week dosing period.
Subjects with more extensive baseline disease (FVASI ≥0.75) showed a 43.2% mean FVASI improvement at week 24 (p=0.006), with 58.8% reaching FVASI50 and 23.5% reaching FVASI75, compared with 0% on placebo. FB102’s safety profile remained favorable, with only mild to moderate treatment-emergent adverse events and no severe events reported.
Federated Hermes, Inc. amended a Schedule 13G/A to report ownership of 2,110,516 shares of Forte Biosciences common stock. The filing shows those shares represent 10.31% of the class as of 06/30/2026. The report includes a Rule 13d-4 disclaimer stating Federated Hermes, the Voting Shares Irrevocable Trust and named individuals expressly disclaim beneficial ownership of securities held by managed funds.